AbbVie Inc (ABBV)vsMicrobot Medical Inc (MBOT)
ABBV
AbbVie Inc
$261.74
+1.79%
HEALTHCARE · Cap: $454.36B
MBOT
Microbot Medical Inc
$1.45
-0.68%
HEALTHCARE · Cap: $98.06M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 18608570% more annual revenue ($64.39B vs $346,000). ABBV leads profitability with a 9.8% profit margin vs 0.0%. ABBV appears more attractively valued with a PEG of 0.52. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
MBOT
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$261.74
$109.92 premium
Margin of Safety
+25.1%
Fair Value
$2.67
Current Price
$1.45
$1.22 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : MBOT
The strongest argument for MBOT centers on Price/Book, Debt/Equity, Altman Z-Score. PEG of 0.70 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : MBOT
The primary concerns for MBOT are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
MBOT carries more volatility with a beta of 1.03 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 34/100) and 10.2% revenue growth. MBOT offers better value entry with a 25.1% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Microbot Medical Inc
HEALTHCARE · MEDICAL DEVICES · USA
Microbot Medical Inc., a preclinical medical device company, researches, designs and develops micro-robotic-assisted medical technologies targeting the minimally invasive surgery space. The company is headquartered in Hingham, Massachusetts.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?